SIGA Technologies Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/. Request email alerts and additional information |
|
KCSA Strategic Communications
Todd Fromer / Marybeth Csaby / Rob Fink
212-896-1215/1236/1206
- 19 Jan 2010 : Israel Taps SIGA Technologies' ST-246(R) to Combat Smallpox in Simulated Bioterror Attack
- 10 Dec 2009 : SIGA Technologies, Inc. Raises $20.0 Million in a Common Stock Offering
- 05 Nov 2009 : SIGA Presents Update on ST-246(R) Development to the World Health Organization
- 02 Nov 2009 : SIGA Technologies to Discuss Third Quarter 2009 Results of Operations on November 9, 2009
- 03 Sep 2009 : SIGA Technologies Inc. Approved for Nasdaq Global Market Listing